ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Biomarkers related to immune checkpoint inhibitors therapy

Li, Na; Hou, Xin; Huang, Shaogang; Tai, Risheng; Lei, Lei; Li, Siyu; Abuliz, Adina; Wang, Geng*; Yang, Shanru*哈尔滨医科大学
Biomedicine and Pharmacotherapy2022-3DOI: 10.1016/j.biopha.2021.112470
9被引9阅读
引用收藏
分享

摘要

Immune checkpoint inhibitors (ICIs) therapy is an emerging cancer treatment. During treatment it is necessary to monitor the patient at all times and respond to any adverse reactions that may occur, such as immune-related adverse events and unconventional reactions. Biomarkers, the biochemical indicators that mark changes in the structure or function of systems, organs, tissues, and cells, may be used to predict and design treatment for such reactions. Anti-tumor immunotherapy biomarkers can be derived from the tumors themselves (e.g. negative regulatory molecules and dynamic changes in genome sequence) or from the immune system (e.g. peripheral blood cell population counts, various cytokines, tumor-infiltrating lymphocytes, and intestinal microbes). The development of biomarkers is important for monitoring the effect of treatment, assessing the patient's response to ICIs, determining adverse reactions, and predicting the direction of disease development. In addition, organ toxicity and systemic events also have an impact on the therapeutic effect of ICIs.

学科与关键词

关键词
BiomarkersICIsIrAEsPD-1PD-L1
相关
加载中…
  • Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer
    Li, Na; Wang, Geng; Hou, Xin; Tai, Risheng; Huang, Shaogang; He, Zhize; Lei, Lei; Xu, Suling*; Yang, Shanru*International Immunopharmacology, 2022, 108: 108803.被引 4
  • Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
    Fan, Jingjing; Shen, Xiangfeng; Wang, Yishu; Zhou, Hong-Lan; Liu, Guolong; Li, Yu-Lin; Xu, Zhi-Xiang*Biomedicine and Pharmacotherapy, 2020, 130: 110621.被引 8
  • New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
    Wang, Yanjun; Yang, Shuo; Wan, Li; Ling, Wei; Chen, Hao*; Wang, Jinghua*International Journal of Oncology, 2023, 63(1): 86.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomedicine and Pharmacotherapy
发表日期
2022-03
卷期
第 147 卷
页码
112470
DOI
10.1016/j.biopha.2021.112470
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
National Nature Science Foundation of China (NSFC) [31741040, 81301023]; Ningbo Natural Science Foundation Project [2021J120]; Ningbo Natural Science Foundation [2021J130]; Fund Program of Heilongjiang Province for Selected Returned Overseas Professionals

作者

  • L

    Li, Na (第一作者)

    ningbo univ

  • H

    Hou, Xin

    ningbo univ

查看全部 9 位作者收起作者
  • H

    Huang, Shaogang

    harbin med univ

  • T

    Tai, Risheng

    harbin med univ

  • L

    Lei, Lei

    harbin med univ

  • L

    Li, Siyu

    ningbo univ

  • A

    Abuliz, Adina

    ningbo univ

  • W

    Wang, Geng (通讯)

    ningbo univ

  • Y

    Yang, Shanru (通讯)

    harbin med univ · ningbo univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417